Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Construction In Progress: €6.0 Mil (As of Dec. 2025)


FRA:I54 Biocytogen Pharmaceuticals (Beijing) Co Ltd FRA:I54
76 GF Score
Price €5.15
GF Value €3.47
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Biocytogen Pharmaceuticals (Beijing) Co Construction In Progress?

Biocytogen Pharmaceuticals (Beijing) Co FRA:I54 +0.98% 76 Construction In Progress is €6.0 Mil as of Dec. 2025. GuruFocus rates FRA:I54 with a GF Score™ of 76/100 and a GF Value™ of €3.47 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Biocytogen Pharmaceuticals (Beijing) Co's quarterly construction in progress declined from Dec. 2024 (€0.2 Mil) to Jun. 2025 (€0.0 Mil) but then increased from Jun. 2025 (€0.0 Mil) to Dec. 2025 (€6.0 Mil).

Biocytogen Pharmaceuticals (Beijing) Co's annual construction in progress declined from Dec. 2023 (€0.7 Mil) to Dec. 2024 (€0.2 Mil) but then increased from Dec. 2024 (€0.2 Mil) to Dec. 2025 (€6.0 Mil).

Biocytogen Pharmaceuticals (Beijing) Co Construction In Progress Historical Data

* Premium members only.

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocytogen Pharmaceuticals (Beijing) Co Construction In Progress Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial 25.28 36.33 0.67 0.25 5.95

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.67 0.00 0.25 0.00 5.95
FRA:I54
76GF Score
Biocytogen Pharmaceuticals (Beijing) Co Ltd FRA:I54
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocytogen Pharmaceuticals (Beijing) Co Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of €6.0 Mil mean?
Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) has a Construction In Progress of €6.0 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors.
Is Biocytogen Pharmaceuticals (Beijing) Co's Construction In Progress too high?
Biocytogen Pharmaceuticals (Beijing) Co's current Construction In Progress is €6.0 Mil. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's Construction In Progress compare to VRTX and REGN?
Biocytogen Pharmaceuticals (Beijing) Co's Construction In Progress of €6.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. Biocytogen Pharmaceuticals (Beijing) Co's current Construction In Progress is €6.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.47, compared to a current price of €5.15 — trading 48.4% above its estimated fair value. The current Construction In Progress is €6.0 Mil. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54), the current Construction In Progress is €6.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Overvalued in 2026?

Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued. The current stock price of €5.15 is trading 48.4% above its estimated GF Value™ of €3.47. GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Significantly Overvalued.

Key valuation signals for FRA:I54:

  • Construction In Progress: €6.0 Mil
  • GF Value™: €3.47 vs. price of €5.15 (48.4% above fair value)
  • GF Score™: 76/100 with 2 warning signs

No single metric tells the full story. See the FRA:I54 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Other Exchanges 02315:Hong Kong688796:China
Address 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
76GF Score

Get the complete analysis for FRA:I54

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.15
Price
€3.47
GF Value